Xencor Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
12analysts covering
FY Revenue (est.)
$143.9Mnext fiscal year
FY EPS (est.)
-$3.11next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| XmAb819 ccRCC Expansion Cohort Data Presentation | 31 Dec 2026 |
| XENITH-UC Phase 2b Blinded Interim Analysis | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Debt Securities Quarterly541.8MTarget: Between $380 million and $400 million by year-end 2026
Quarterly Revenue Quarterly4.5M
Quarterly Research and Development (R&D) Expenses Quarterly64.7M
Watch Items
- XmAb819 Phase 1 Expansion Cohort Data PresentationTrigger: Presentation of clinical data to support a recommended Phase 3 dose in ccRCCAction: Evaluate overall response rate (ORR), disease control rate (DCR), and safety profile to confirm readiness for the planned 2027 pivotal study.
- XmAb942 (Xtend anti-TL1A) Phase 2b XENITH-UC Study Blinded Interim AnalysisTrigger: Completion of blinded interim analysis around year-end 2026Action: Assess trial progression and enrollment metrics to ensure the study remains on track for primary endpoint results in H2 2027.
- XmAb412 (TL1A x IL23p19) First-in-Human Study InitiationTrigger: Initiation of Phase 1 study in healthy participants in 3Q 2026Action: Monitor initial safety, tolerability, pharmacokinetics, and pharmacodynamics to validate the XenLock bispecific platform.
- Alexion Royalty Dispute and Ultomiris Royalty Term ExtensionTrigger: Resolution of disputed U.S. sales royalties and execution of the extended royalty term through year-end 2028Action: Track cash inflows from Ultomiris royalties to confirm the estimated additional $100 million to $120 million in potential revenue.
Research as of 19 Jun 2026